Instant insights from a pioneer of preemptive pharmacogenomic research
Metabolizer status can be misclassified based on pharmacogenomic genotyping if population genetic diversity is missed.
In this webinar, Dr. Ulrich Broeckel, Professor at Medical College of Wisconsin and founder and CEO of RPRDx, talks about healthcare disparities in genetically diverse populations, illustrates the dangers with a case study of CYP2D6 misclassification and explains how solutions like Axiom PharmacoFocus Assay enable comprehensive variant analysis to minimise risk of error in research studies.